Open Nav

Sermonix Pharmaceuticals LLC

  • David Portman, Sermonix Pharmaceuticals LLC

Funding for Phase 2 development program

  • Date:Wednesday, October 17
  • Time:4:00 PM - 4:15 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Sermonix is a clinical stage biopharma company focused on metastatic breast cancer (mBC) with a mission to solve the problem of acquired endocrine resistance in mBC in the presence of ESR1 mutations. All patients with mBC ultimately progress, and there is a clear lack of efficacious, well-tolerated options after first line failure. Sermonix is developing the extensively studied potent selective estrogen receptor modulator (SERM), lasofoxifene, as a new, targeted endocrine treatment for Estrogen Receptor Positive (ER+) mBC patients with acquired endocrine resistance due to ESR1 mutations. Lasofoxifene is supported by strong in vivo proof of concept in mutation driven resistance, class-leading in vivo activity against visceral metastases, and new late-expiring IP out to 2037. The Sermonix management team has proven success and experience in developing drugs in breast cancer. An IND opens in October 2018, clinical trial results reporting in 2020, and significant value creation in 2-3 yrs
  • Company Website:www.sermonixpharma.com
  • Company HQ City:Columbus
  • Company HQ Country:United States
  • Company HQ State:Ohio                              
  • CEO/Top Company Official:David J Portman, MD
  • Year Founded:2014
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Lasofoxifene
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :One
  • Additional Information/Comments:Lasofoxifene has a $800M+ annual peak U.S. sales potential based on proprietary primary market research. Sermonix’s lasofoxifene development benefits from the vast prior development by Pfizer focused on osteoporosis and non-oncology indications for which founder Dr David Portman was principal investigator and advisor. Over 10,000 patients were treated in six Phase 3 and multiple other studies. An 83% reduction in ER+ breast cancer was seen in the five-year PEARL osteoporosis trial of over 8,500 women. The FDA has agreed fully in a PIND meeting to Sermonix enriched Phase 2 trial design, dose, and ongoing cGMP-API manufacturing process. Sermonix has a seasoned existing investor base with extensive executive biopharma experience and successful exits in the sector.
  • Previous and Current Investors:Anthony Wild, Richard de Schutter, W. Robert Dahl Jr, Endoresearch
  • Size of Last Investment Round:$2.3M
  • Total Amount Raised to Date, In All Rounds:$10.5M
Speakers
David Portman
Sermonix Pharmaceuticals LLC
Back